EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Ruyu Yan iD, Jeong Eun Min, Megan Kurz iD, Shaun R Seaman, Paxton Bach iD, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías und 2 weitere

Addiction · 2026

DOI: 10.1111/add.70489 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Addiction, 2026. Verfasst von Ruyu Yan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment, Analgesics, Opioid, Drug Tapering. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, Health Canada Substance Use and Addictions Program, National Institutes of Health/National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment. Current clinical practice guidelines offer relatively limited guidance or evidence on the appropriate timing to initiate a taper. We aimed to determine the safety and comparative effectiveness of different times from completion of OAT induction at which tapering could be considered to maximize the likelihood of taper completion and minimize the risk of mortality.

Design

Population‐based retrospective observational study and target trial emulation based on nine linked administrative health databases.

Setting

British Columbia, Canada, from 1 January 2010 to 17 March 2020.

Participants

Individuals (identified via linkage of nine provincial health administrative databases) completing OAT induction with methadone or buprenorphine/naloxone who were ≥18 years of age with no known pregnancy, no history of cancer or palliative care and not currently incarcerated. We executed both incident‐user (no OAT experiences) and prevalent‐new‐user (no OAT within the past month) analyses. Intervention and comparator The time between completed OAT induction and taper initiation:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersOpiate Substitution TreatmentAnalgesics, OpioidDrug TaperingBuprenorphine, Naloxone Drug CombinationHumansBritish ColumbiaRetrospective StudiesMethadoneFemaleAdultMaleMiddle AgedTime FactorsBuprenorphineNarcotic AntagonistsCause of Death

Stichwörter der Autor:innen

buprenorphine/naloxoneclone–censor–weight approachcomparative effectivenessmethadoneopioid agonist treatmentopioid use disordertaper initiationtarget trial

Substanzen

MethadoneAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationBuprenorphineNarcotic Antagonists

Autor:innen und Institutionen

  • Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Medical Research Council (MRC) Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • British Columbia Centre on Substance Use (BCCSU), Vancouver, British Columbia, Canada.
  • Department of Medicine, UBC Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Epidemiology and Department of Statistics, The University of California, Los Angeles, Los Angeles, California, USA.

ORCID-Profile: Ruyu Yan, Megan Kurz, Paxton Bach

Förderung

  • NIDA NIH HHS
  • Health Canada Substance Use and Addictions Program
  • National Institutes of Health/National Institute on Drug Abuse

Zitieren

APA

Yan, R., Min, J. E., Kurz, M., Seaman, S. R., Bach, P., Greenland, S., Gustafson, P., Karim, M. E., McCandless, L., Platt, R. W., Siebert, U., Socías, M. E., Xie, H., & Nosyk, B. (2026). Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020. Addiction. https://doi.org/10.1111/add.70489

Vancouver

Yan R, Min JE, Kurz M, Seaman SR, Bach P, Greenland S, et al. Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020. Addiction. 2026. doi:10.1111/add.70489

BibTeX
@article{Yan2026,
  author = {Yan, Ruyu and Min, Jeong Eun and Kurz, Megan and Seaman, Shaun R and Bach, Paxton and Greenland, Sander and Gustafson, Paul and Karim, Mohammad Ehsanul and McCandless, Lawrence and Platt, Robert William and Siebert, Uwe and Socías, María Eugenia and Xie, Hui and Nosyk, Bohdan},
  title = {Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020},
  journal = {Addiction},
  year = {2026},
  doi = {10.1111/add.70489}
}
Kostenlos starten →